Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Gamida Cell (GMDA) yesterday and set a price target of $17.00. The company’s shares closed last Monday at $9.09.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 18.3% and a 45.1% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.
Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $15.00, an 82.3% upside from current levels. In a report issued on December 3, RBC Capital also maintained a Buy rating on the stock with a $13.00 price target.
See today’s analyst top recommended stocks >>
Gamida Cell’s market cap is currently $490.8M and has a P/E ratio of -6.90. The company has a Price to Book ratio of 8.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
